Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21098749 | 0.95 | SMN1; SMN2 (0.42) | MAPTSMN1; SMN2RAB9ABRD4NPC1 | |
| SCHEMBL21098752 | 0.95 | SMN1; SMN2 (0.40) | MAPTSMN1; SMN2RAB9ABRD4NPC1 | |
| SCHEMBL21052174 | 0.95 | SMN1; SMN2 (0.42) | MAPTSMN1; SMN2RAB9ABRD4NPC1 | |
| SCHEMBL30231974 | 0.95 | SMN1; SMN2 (0.42) | MAPTSMN1; SMN2RAB9ABRD4NPC1 | |
| SCHEMBL21098680 | 0.88 | SMN1; SMN2 (0.43) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL21098696 | 0.88 | SMN1; SMN2 (0.43) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL22773544 | 0.87 | MAPT (0.37) | MAPTSMN1; SMN2RAB9ABRD4NPC1 | |
| SCHEMBL22577953 | 0.87 | MAPT (0.37) | MAPTSMN1; SMN2RAB9ABRD4NPC1 | |
| SCHEMBL23226030 | 0.87 | BRD4 (0.34) | MAPTSMN1; SMN2BRD4 | |
| SCHEMBL22802051 | 0.86 | BRD4 (0.33) | SMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-02-14 | — | — | US | disclosed |
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-24 | — | — | US | disclosed |
| WO-2019109188-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | KAT7, AADAC, HDAC7 | MAPT 3413/4885SMN1; SMN2 4352/4885RAB9A 4231/4885 |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | AADAC, HDAC8, KAT8 | MAPT 3082/4885SMN1; SMN2 3796/4885RAB9A 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.